Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2015

View Archived Issues

ProMetic partners with ProThera to develop plasma-derived IAIP

Spring Bank plans phase II trial of SB-9200 and Viread in HBV infection

University of Adelaide to conduct phase I study of AmpliPhi's AB-SA01

Galapagos begins phase I study of GLPG-1972

Daiichi Sankyo doses first subject in phase I study using Anticalin technology

Boston Pharmaceuticals launched to develop drugs for complex diseases

Autologous CBL-B-silenced cell therapy is feasible in patients with solid tumors

MediciNova to begin phase IIa study of MN-001 for hypertriglyceridemia in patients with NASH

Phase Ib trial of Aptose's APTO-253 placed on hold

Immune responses, survival improvements seen with uveal melanoma DC vaccine

Benepali is first biosimilar etanercept recommended for approval in E.U.

Vitamin D analogue DP-001 may be superior for treating secondary hyperparathyroidism

First preclinical results presented for a novel, noncovalent BTK inhibitor

CHMP recommends approval of Briviact

AstraZeneca patents ATM kinase inhibitors

Kineta discloses antiviral RIG-I pathway modulators

Bristol-Myers Squibb reports GPR40 modulators

U.S. Department of Health & Human Services introduces CB1 receptor ligands

Merck KGaA patents PARP-1/TNKS inhibitors

NEO-214 shows efficacy against gliomas

AstraZeneca sells U.S. rights to Entocort to Perrigo

Pharmacological chaperone shows promise for GM1 and Morquio B lysosomal diseases

CHMP recommends approval of Episalvan to treat partial thickness wounds in adults

Metastatic colorectal cancer study shows administration of neratinib with cetuximab is feasible

FDA clears IND for phase IIa trial of Generon's F-652 for alcoholic hepatitis

FDA approves Opdivo for renal cell carcinoma

European Commission approves Elocta for hemophilia A

European Comission grants two landmark approvals to Novartis' Consentyx

European Commission gives conditional marketing authorization to Blincyto

Gilead Sciences' Genvoya approved in E.U. for HIV-1 infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...